tickdelta
Sign in
Screener / SEC EDGAR /CIK 0001022079 /10-K filed Feb 26, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
VRTXHSICBAXISRGBIIBDGX
NYSE Health care · Medical Labs

Quest Diagnostics DGX

DGX quote by TradingView

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. 10-K, Item 1

Employees
57,000
Headquarters
Secaucus, NJ
CEO
J. E. Davis
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $11.0B through the costs to a net profit of $992.0M · income statement of the 10-K

14% operating margin
Revenue to Gross profit: $3.7BRevenue to Cost of revenue: $7.4BGross profit to Operating profit: $1.6BGross profit to Operating expenses: $2.1BOperating profit to Net profit: $992.0MOperating profit to Tax & other: $564.0M Revenue: $11.0B REVENUE $11.0B +12% Y/Y Gross profit: $3.7B · 33% margin GROSS PROFIT $3.7B 33% margin Cost of revenue: $7.4B · 67% of revenue COST OF REVENUE $7.4B 67% of revenue Operating profit: $1.6B · 14% margin OPERATING PROFIT $1.6B 14% margin · +16% Y/Y Operating expenses: $2.1B · 19% of revenue OPERATING EXPENSES $2.1B 19% of revenue Net profit: $992.0M · 9% margin NET PROFIT $992.0M 9% margin · +14% Y/Y Tax & other: $564.0M · 5% of revenue TAX & OTHER $564.0M 5% of revenue
Gross profit $3.7B 33% margin
Operating profit $1.6B 14% margin · +16% Y/Y
Net profit $992.0M 9% margin · +14% Y/Y
The full income statement, year by year

DGX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 11.8%, above 80% of 59 peers (their median 7.1%) REVENUE GROWTH 11.8% · above 80% Gross margin: 33.1%, above 18% of 50 peers (their median 65.2%) GROSS MARGIN 33.1% · above 18% Operating margin: 14.6%, above 54% of 50 peers (their median 13.4%) OPERATING MARGIN 14.6% · above 54% Net margin: 9.5%, above 49% of 59 peers (their median 9.7%) NET MARGIN 9.5% · above 49% FCF margin: 11.6%, above 36% of 55 peers (their median 15.8%) FCF MARGIN 11.6% · above 36% Return on capital: 9.0%, above 46% of 41 peers (their median 9.2%) RETURN ON CAPITAL 9.0% · above 46%
DGX Peer median Below the median

What changed

3 new risk paragraphs. 10-K filed Feb 26, 2026 against Feb 20, 2025.

Risk factors
3 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
11 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
11 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +8.0% vs revenue +11.8% (-3.8 pts)
  • Cash from operations $1.9B vs net income $992.0M (FY ending Dec 31, 2025)
  • Inventory +0.5% vs revenue +11.8% (-11.2 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No longer listed: Acquisition of LifeLabs - Valuation of Customer-Related and Trade Name Intangible Assets; F-2. Same as last year: Valuation of Diagnostic Information Services (DIS) Business Accounts Receivable - Contractual Allowances
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

3 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.

All 3 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    •the laws and regulations administered by foreign governments where we conduct clinical trials and operate outside of the United States;
  2. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    threatened by the U.S. government, and the responses to those actions from other countries, may result in adverse impacts to the global economic environment, including the global financial and trading markets, which could have a negative impact on our results of operations and financial condition. These actions could also negatively…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    (p) Challenges, including the associated competitive pressures, with properly managing the development, implementation, oversight and use of AI.

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$9.9B$9.3B$9.9B$11.0B
Net income$946.0M$854.0M$871.0M$992.0M
Operating cash flow$1.7B$1.3B$1.3B$1.9B
Free cash flow$1.3B$864.0M$909.0M$1.4B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$11.0B ▲ 11.8% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

11 filings in the last 30 days · SEC EDGAR

All filings
6 more

About the company

Quest Diagnostics, Secaucus, NJ · from the 10-K filed Feb 26, 2026

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. In the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world.

Headquarters
Secaucus, NJ
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 22, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we have nearly 57,000 employees globally (including LifeLabs’ approximately 6,800), of whom approximately 46,000 are full-time and the remainder are part-time or on-call" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/DGX/export.csv") into a cell.